STOCK TITAN

Vanguard disaggregates holdings after realignment — Chemed (CHE) shows 0 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Chemed Corp (CHE) Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Chemed common stock, representing 0% of the class as disclosed in the filing dated 03/13/2026. The filing explains an internal realignment at Vanguard on 01/12/2026 that caused disaggregated reporting by subsidiaries; no beneficial ownership is claimed here.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership and cites an internal realignment.

The amendment states 0 shares and 0% ownership as of the disclosed filing, and it attributes separate reporting to subsidiaries after an internal realignment on 01/12/2026. This is a reporting adjustment rather than a trading disclosure.

Cash‑flow treatment and any prior holdings are not disclosed in the excerpt; subsequent filings or prior schedules would show historical positions if relevant.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Chemed Corp's Schedule 13G/A from Vanguard (CHE) show?

It shows The Vanguard Group reports 0 shares and 0% beneficial ownership of Chemed common stock in this amendment. The filing cites a Vanguard internal realignment on 01/12/2026 as the reason for disaggregated reporting by subsidiaries.

Does this Schedule 13G/A indicate Vanguard sold Chemed (CHE) shares?

The amendment reports 0 shares beneficially owned but does not state transaction activity. It attributes separate subsidiary reporting after an internal realignment; direct sale or purchase details are not included in the provided excerpt.

Why does Vanguard report separately after 01/12/2026 in the filing for CHE?

Per the filing, Vanguard underwent an internal realignment on 01/12/2026, causing subsidiaries or business divisions to report beneficial ownership separately in reliance on SEC Release No. 34-39538, which the amendment quotes verbatim.

Who signed the Schedule 13G/A amendment for Vanguard regarding CHE?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026. The filing lists Vanguard's address as 100 Vanguard Blvd., Malvern, PA.
Chemed Corp

NYSE:CHE

View CHE Stock Overview

CHE Rankings

CHE Latest News

CHE Latest SEC Filings

CHE Stock Data

5.15B
13.49M
Medical Care Facilities
Services-home Health Care Services
Link
United States
CINCINNATI